{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:23:45Z","timestamp":1773185025740,"version":"3.50.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in the United States in 2010. We describe invasive pneumococcal disease (IPD) in children at 8 children\u2019s hospitals in the United States from 2018 to 2023, when PCV20 was licensed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Children with IPD occurring from 2018 to 2023 were identified from a database of a prospective study. Demographic and clinical data were recorded on case report forms. Isolate serotypes were determined in a central laboratory. Antibiotic susceptibilities were determined by minimal inhibitory testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      During 2018\u20132023, PCV13 serotypes accounted for 32% (128\/404) and 28% (66\/234) of IPD isolates from children &lt;5 and \u22655 years old, respectively. Nearly all were serotypes 3, 19A and 19F. The 7 new PCV20 serotypes accounted for 25% of IPD in children &lt;5 and 19% among children \u22655 years old. Other common non-PCV13 serotypes were 35B (9.2%) and 23B (7.5%). Underlying conditions were recorded for 45.5% (184\/404) and 66.7% (156\/234), respectively, for children &lt;5 years of age and \u22655 years of age with an isolate available (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Among 109 meningitis isolates, 11 (10.1%) were nonsusceptible to ceftriaxone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PCV13 serotypes (especially 3, 19A and 19F) continue to account for 30% of IPD in US children 8\u201313 years after PCV13 was introduced. Vancomycin should still be included in empiric treatment of bacterial meningitis in children. The introduction of PCV20 for routine administration to infants could result in further reductions in IPD in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005039","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:01:05Z","timestamp":1762491665000},"page":"300-306","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Invasive Pneumococcal Disease at Eight Children\u2019s Hospitals in the United States, 2018\u20132023"],"prefix":"10.1097","volume":"45","author":[{"given":"Sheldon L.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Barson","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, College of Medicine and Public Health, Ohio State University, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philana","family":"Ling Lin","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Dahl","sequence":"additional","affiliation":[{"name":"Arkansas Children\u2019s Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital San Diego, University of California, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia S.","family":"Pannaraj","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital San Diego, University of California, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina Q.","family":"Tan","sequence":"additional","affiliation":[{"name":"Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Dien","family":"Bard","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Keck School of Medicine, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacy","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Brenner Children\u2019s Hospital, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay R.","family":"Grant","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Arguedas","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Tort","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Miller","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Can\u00e9","sequence":"additional","affiliation":[{"name":"Pfizer, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina G.","family":"Hulten","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R1-20260310","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R2-20260310","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.2014-0473","article-title":"Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine.","volume":"134","author":"Iroh Tam","year":"2014","journal-title":"Pediatrics"},{"key":"R3-20260310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jpids\/piw005","article-title":"The effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease.","volume":"6","author":"Gaviria-Agudelo","year":"2017","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R4-20260310","doi-asserted-by":"crossref","first-page":"e20190567","DOI":"10.1542\/peds.2019-0567","article-title":"Invasive pneumococcal disease in children\u2019s hospitals: 2014-2017.","volume":"144","author":"Kaplan","year":"2019","journal-title":"Pediatrics"},{"key":"R6-20260310","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jpids\/piaa035","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use.","volume":"10","author":"Baxter","year":"2021","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R7-20260310","doi-asserted-by":"crossref","first-page":"e2023063039","DOI":"10.1542\/peds.2023-063039","article-title":"Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use.","volume":"153","author":"Yildirim","year":"2024","journal-title":"Pediatrics"},{"key":"R8-20260310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/infdis\/jiac154","article-title":"Impact of pneumococcal conjugate vaccines on antibiotic-nonsusceptible invasive pneumococcal disease in the United States.","volume":"226","author":"Bajema","year":"2022","journal-title":"J Infect Dis"},{"key":"R9-20260310","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of the 15-valent pneumococcal conjugate vaccine among U.S. children: Updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2020.","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R11-20260310","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.annemergmed.2016.01.042","article-title":"Clinical policy for well-appearing infants and children younger than 2 years of age presenting to the emergency department with fever.","volume":"67","author":"Mace","year":"2016","journal-title":"Ann Emerg Med"},{"key":"R13-20260310","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jpids\/piac056","article-title":"Decrease in pediatric invasive pneumococcal disease during the COVID-19 pandemic.","volume":"11","author":"Sarmiento Clemente","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R15-20260310","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3201\/eid2808.220304","article-title":"Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England.","volume":"28","author":"Bertran","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"R16-20260310","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1093\/cid\/ciac475","article-title":"Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination.","volume":"76","author":"Grant","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R17-20260310","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.vaccine.2017.12.035","article-title":"Re-emergence of pneumococcal colonization by vaccine serotype 19F in persons aged \u22655 years after 13-valent pneumococcal conjugate vaccine introduction\u2014Alaska, 2008-2013.","volume":"36","author":"Gounder","year":"2018","journal-title":"Vaccine"},{"key":"R18-20260310","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.vaccine.2017.06.047","article-title":"Colonization with 19F and other pneumococcal conjugate vaccine serotypes in children in St. Louis, Missouri, USA.","volume":"35","author":"McFarland","year":"2017","journal-title":"Vaccine"},{"key":"R19-20260310","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"R20-20260310","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R21-20260310","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2024.04.061","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study.","volume":"42","author":"Andrejko","year":"2024","journal-title":"Vaccine"},{"key":"R22-20260310","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/cid\/ciy920","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies.","volume":"68","author":"Sings","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R23-20260310","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1016\/j.vaccine.2018.07.069","article-title":"Commentary on paradoxical observations pertaining to the impact of the 13 valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children.","volume":"36","author":"De Wals","year":"2018","journal-title":"Vaccine"},{"key":"R24-20260310","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/INF.0000000000004192","article-title":"Serotype 3 antibody response and antibody functionality compared to serotype 19A following 13-valent pneumococcal conjugate immunization in children.","volume":"43","author":"Fuji","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20260310","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/genes10110845","article-title":"Evolution of Streptococcus pneumoniae serotype 3 in England and Wales: a major vaccine evader.","volume":"10","author":"Groves","year":"2019","journal-title":"Genes (Basel)"},{"key":"R26-20260310","first-page":"001196","article-title":"Streptococcus pneumoniae serotype 3 population structure in the era of conjugate vaccines, 2001-2018.","volume":"10","author":"Cella","year":"2024","journal-title":"Microb Genom"},{"key":"R27-20260310","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.vaccine.2022.06.041","article-title":"Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.","volume":"40","author":"Hao","year":"2022","journal-title":"Vaccine"},{"key":"R28-20260310","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal vaccine, V116 (STRIDE-3): a randomized, double-blind, active comparator controlled, international phase 3 trial.","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"R30-20260310","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/JCM.01778-16","article-title":"Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States.","volume":"55","author":"Olarte","year":"2017","journal-title":"J Clin Microbiol"},{"key":"R31-20260310","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3201\/eid2306.170071","article-title":"Invasive serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015-2016.","volume":"23","author":"Chochua","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R32-20260310","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2666-5247(22)00158-6","article-title":"Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study.","volume":"3","author":"Lo","year":"2022","journal-title":"Lancet Microbe"},{"key":"R33-20260310","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/ciaa917","article-title":"Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation.","volume":"72","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R34-20260310","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1017\/S0950268822000395","article-title":"Epidemiological characteristics in serotype 24 paediatric invasive pneumococcal disease according to an 11-year population-based study in Japan.","volume":"150","author":"Takeshita","year":"2022","journal-title":"Epidemiol Infect"},{"key":"R35-20260310","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1016\/j.vaccine.2021.08.072","article-title":"Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014-2019.","volume":"39","author":"Yun","year":"2021","journal-title":"Vaccine"},{"key":"R36-20260310","doi-asserted-by":"crossref","first-page":"piaf056","DOI":"10.1093\/jpids\/piaf056","article-title":"Pediatric invasive pneumococcal disease spectrum before third-generation pneumococcal conjugate vaccine implementation.","volume":"14","author":"Levy","year":"2025","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R37-20260310","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014-2018.","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R38-20260310","doi-asserted-by":"crossref","first-page":"e2021051892","DOI":"10.1542\/peds.2021-051892","article-title":"Bloodstream infections in children with Sickle Cell disease: 2010-2019.","volume":"149","author":"Yee","year":"2022","journal-title":"Pediatrics"},{"key":"R39-20260310","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/archdischild-2024-327497","article-title":"Epidemiology of childhood invasive pneumococcal disease in Australia: a prospective cohort study.","volume":"110","author":"Phuong","year":"2024","journal-title":"Arch Dis Child"},{"key":"R40-20260310","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jpids\/piy121","article-title":"Vancomycin should be part of empiric therapy for suspected bacterial meningitis.","volume":"8","author":"Olarte","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R41-20260310","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","article-title":"Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.","volume":"3","author":"Brueggemann","year":"2021","journal-title":"Lancet Digit Health"},{"key":"R42-20260310","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/cid\/ciaa1728","article-title":"Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England.","volume":"72","author":"Amin-Chowdhury","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R43-20260310","doi-asserted-by":"crossref","first-page":"e2218959","DOI":"10.1001\/jamanetworkopen.2022.18959","article-title":"Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France.","volume":"5","author":"Rybak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R44-20260310","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciac100","article-title":"Remergence of invasive pneumococcal disease in Germany during the spring and summer of 2021.","volume":"75","author":"Perniciaro","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R45-20260310","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1080\/22221751.2021.2000892","article-title":"Re-emergence of invasive pneumococcal disease (IPD) and increase of serotype 23B after easing of COVID-19 measures, Switzerland, 2021.","volume":"10","author":"Casanova","year":"2021","journal-title":"Emerg Microbes Infect"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:02:37Z","timestamp":1773115357000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005039","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}